Form 4 for KPTI Karyopharm Therapeutics Inc.
Accepted 2025-09-16 00:00:00 ET · period of report 2025-09-12 · accession 0001193125-25-205042 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-09-16 | 2025-09-12 | KPTI | Cheng Sohanya Roshan | EVP, Chief Commercial Off | A - Grant | $0.00 | +945 | 36.2K | +3% | $0 | |
| 2025-09-16 | 2025-09-15 | KPTI | Cheng Sohanya Roshan | EVP, Chief Commercial Off | S - Sale | $6.43 | -325 | 35.9K | -0.9% | -$2,090 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-09-12 | A | A | 945 | $0.00 | 36,181 | D | — | — | (F1) Represents the number of shares of the issuer's common stock underlying performance-based restricted stock units ("PSUs") granted in February 2023 that have been earned based on the level of achievement of the clinical milestone for complete enrollment in the Company's Phase 3 SENTRY trial, as certified by the issuer's Compensation Committee on September 12, 2025. Each earned PSU represents the contingent right to receive one share of the issuer's common stock upon vesting. The earned PSUs vested on September 12, 2025. (F2) Includes 922 shares acquired by the reporting person under the Karyopharm Therapeutics Inc. Amended & Restated 2013 Employee Stock Purchase Plan on April 30, 2025. |
| 2 | Common | Common Stock | 2025-09-15 | S | D | 325 | $6.43 | 35,856 | D | — | — |